Books > Business & Economics > Business & management > Management & management techniques > Operational research
|
Buy Now
Optimization of Pharmaceutical R&D Programs and Portfolios - Design and Investment Strategy (Paperback, Softcover reprint of the original 1st ed. 2015)
Loot Price: R5,504
Discovery Miles 55 040
|
|
Optimization of Pharmaceutical R&D Programs and Portfolios - Design and Investment Strategy (Paperback, Softcover reprint of the original 1st ed. 2015)
Expected to ship within 10 - 15 working days
|
Donate to Against Period Poverty
Total price: R5,524
Discovery Miles: 55 240
|
Very little has been published on optimization of pharmaceutical
portfolios. Moreover, most of published literature is coming from
the commercial side, where probability of technical success (PoS)
is treated as fixed, and not as a consequence of development
strategy or design. In this book there is a strong focus on impact
of study design on PoS and ultimately on the value of portfolio.
Design options that are discussed in different chapters are
dose-selection strategies, adaptive design and enrichment. Some
development strategies that are discussed are indication
sequencing, optimal number of programs and optimal decision
criteria. This book includes chapters written by authors with very
broad backgrounds including financial, clinical, statistical,
decision sciences, commercial and regulatory. Many authors have
long held executive positions and have been involved with decision
making at a product or at a portfolio level. As such, it is
expected that this book will attract a very broad audience,
including decision makers in pharmaceutical R&D, commercial and
financial departments. The intended audience also includes
portfolio planners and managers, statisticians, decision scientists
and clinicians. Early chapters describe approaches to portfolio
optimization from big Pharma and Venture Capital standpoints. They
have stronger focus on finances and processes. Later chapters
present selected statistical and decision analysis methods for
optimizing drug development programs and portfolios. Some
methodological chapters are technical; however, with a few
exceptions they require a relatively basic knowledge of statistics
by a reader.
General
Is the information for this product incomplete, wrong or inappropriate?
Let us know about it.
Does this product have an incorrect or missing image?
Send us a new image.
Is this product missing categories?
Add more categories.
Review This Product
No reviews yet - be the first to create one!
|
|
Email address subscribed successfully.
A activation email has been sent to you.
Please click the link in that email to activate your subscription.